Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

The Lancet Oncology

Volumn 17, Issue 10, 2016, Pages 1374-1385

  Kaufman, Howard L ^a   Russell, Jeffery ^b   Hamid, Omid ^c   Bhatia, Shailender ^d   Terheyden, Patrick ^e   D'Angelo, Sandra P ^f   Shih, Kent C ^g   Lebbé, Céleste ^h   Linette, Gerald P ⁱ   Milella, Michele ^j   Brownell, Isaac ^k   Lewis, Karl D ^l   Lorch, Jochen H ^m   Chin, Kevin ⁿ   Mahnke, Lisa ⁿ   von Heydebreck, Anja ^o   Cuillerot, Jean Marie ⁿ   Nghiem, Paul ^d  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Angeles Clinic and Research Institute   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e UNIVERSITY OF LÜBECK   (Germany)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^k NATIONAL CANCER INSTITUTE   (United States)

^l UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ EMD Serono   (United States)

^o MERCK KGAA   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AVELUMAB; CHOLESTEROL; CREATINE KINASE; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; ASIA; ASTHENIA; AUSTRALIA; CANCER CHEMOTHERAPY; CANCER STAGING; CELLULITIS; CHONDROCALCINOSIS; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOLITIS; EUROPE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFUSION RELATED REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INTENTION TO TREAT ANALYSIS; INTERSTITIAL NEPHRITIS; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; MULTICENTER STUDY; NAUSEA; NORTH AMERICA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SINGLE BLIND PROCEDURE; SYNOVITIS; ANTAGONISTS AND INHIBITORS; CARCINOMA, MERKEL CELL; CLINICAL TRIAL; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN NEOPLASMS;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CARCINOMA, MERKEL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84992340907     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30364-3     Document Type: Article

References (42)

1. 1 Agelli, M, Clegg, LX, Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 49 (2003), 832–841.
2. 2 Feng, H, Shuda, M, Chang, Y, Moore, PS, Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319 (2008), 1096–1100.
3. 3 Lebbé, C, Becker, JC, Grob, JJ, et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer 51 (2015), 2396–2403.
4. 4 Fitzgerald, TL, Dennis, S, Kachare, SD, Vohra, NA, Wong, JH, Zervos, EE, Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surg 81 (2015), 802–806.
5. 5 Youlden, DR, Soyer, HP, Youl, PH, Fritschi, L, Baade, PD, Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993–2010. JAMA Dermatol 150 (2014), 864–872.
6. 6 Allen, PJ, Bowne, WB, Jaques, DP, Brennan, MF, Busam, K, Coit, DG, Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 23 (2005), 2300–2309.
7. 7 Lemos, BD, Storer, BE, Iyer, JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63 (2010), 751–761.
8. 8 Tai, PT, Yu, E, Winquist, E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18 (2000), 2493–2499.
9. 9 Santamaria-Barria, JA, Boland, GM, Yeap, BY, Nardi, V, Dias-Santagata, D, Cusack, JC Jr, Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol 20 (2013), 1365–1373.
10. 10 Voog, E, Biron, P, Martin, JP, Blay, JY, Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85 (1999), 2589–2595.
11. 11 Iyer, JG, Blom, A, Doumani, R, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med, 2016, 10.1002/cam4.815 published online July 19.
12. 12 Sharma, D, Flora, G, Grunberg, SM, Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature. Am J Clin Oncol 14 (1991), 166–169.
13. 13 Satpute, SR, Ammakkanavar, NR, Einhorn, LH, Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings. Proc Am Soc Clin, 32(suppl 5S), 2014 abstr 9049.
14. 14 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Merkel cell carcinoma. https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf, 2016 (accessed Aug 17, 2016).
15. 15 Desch, L, Kunstfeld, R, Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer, 2013, 2013, 327150.
16. 16 Santos-Juanes, J, Fernandez-Vega, I, Fuentes, N, et al. Merkel cell carcinoma and Merkel cell polyomavirus: a systematic review and meta-analysis. Br J Dermatol 173 (2015), 42–49.
17. 17 Rodig, SJ, Cheng, J, Wardzala, J, et al. Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 122 (2012), 4645–4653.
18. 18 Bhatia, S, Afanasiev, O, Nghiem, P, Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep 13 (2011), 488–497.
19. 19 Wong, SQ, Waldeck, K, Vergara, IA, et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res 75 (2015), 5228–5234.
20. 20 Goh, G, Walradt, T, Markarov, V, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7 (2016), 3403–3415.
21. 21 Harms, PW, Vats, P, Verhaegen, ME, et al. The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res 75 (2015), 3720–3727.
22. 22 Heath, M, Jaimes, N, Lemos, B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 58 (2008), 375–381.
23. 23 Paulson, KG, Iyer, JG, Blom, A, et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J Invest Dermatol 133 (2013), 642–646.
24. 24 Dong, H, Strome, SE, Salomao, DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002), 793–800.
25. 25 Hirano, F, Kaneko, K, Tamura, H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 (2005), 1089–1096.
26. 26 Iwai, Y, Ishida, M, Tanaka, Y, Okazaki, T, Honjo, T, Minato, N, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99 (2002), 12293–12297.
27. 27 Patel, SP, Kurzrock, R, PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14 (2015), 847–856.
28. 28 Aguiar, PN Jr, Santoro, IL, Tadokoro, H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy 8 (2016), 479–488.
29. 29 Lipson, EJ, Vincent, JG, Loyo, M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 1 (2013), 54–63.
30. 30 Afanasiev, OK, Yelistratova, L, Miller, N, et al. Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 19 (2013), 5351–5360.
31. 31 Iyer, JG, Afanasiev, OK, McClurkan, C, et al. Merkel cell polyomavirus-specific CD8(+) and CD4(+) T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 17 (2011), 6671–6680.
32. 32 Nghiem, PT, Bhatia, S, Lipson, EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374 (2016), 2542–2552.
33. 33 Heery, CR, O'Sullivan Coyne, G, Madan, RA, et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. Proc Am Soc Clin Oncol, 32(suppl 5S), 2014 abstr 3064.
34. 34 Boyerinas, B, Jochems, C, Fantini, M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3 (2015), 1148–1157.
35. 35 Heery, CR, O'Sullivan Coyne, G, Marte, JL, et al. Pharmacokinetic profile and receptor occupancy of avelumab (MSB00110718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors. Proc Am Soc Clin Oncol, 33(suppl), 2015 abstr 3055.
36. 36 Kelly, K, Patel, MR, Infante, JR, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. Proc Am Soc Clin Oncol, 33(suppl), 2015 abstr 3044.
37. 37 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
38. 38 Shuda, M, Arora, R, Kwun, HJ, et al. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer 125 (2009), 1243–1249.
39. 39 Wolchok, JD, Hoos, A, O'Day, S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
40. 40 Jennison, C, Turnbull, BW, Group sequential methods with applications to clinical trials, 2000, Chapman & Hall/CRC, Boca Raton, FL.
41. 41 Veness, MJ, Perera, L, McCourt, J, et al. Merkel cell carcinoma: improved outcome with adjuvant radiotherapy. ANZ J Surg 75 (2005), 275–281.
42. 42 Weber, JS, Yang, JC, Atkins, MB, Disis, ML, Toxicities of immunotherapy for the practitioner. J Clin Oncol 33 (2015), 2092–2099.